Managing dyslipidemia in patients with Type 2 diabetes

References

• Cameron NA, Petito LC, McCabe M, et al. Quantifying the sex‐race/ethnicity‐specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES. J Am Heart Assoc. 2021;e018799.
   PubMed Web of Science ®Google Scholar
• Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56(4):686–695.
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6(7):538–546. .
   PubMed Web of Science ®Google Scholar
• Sattar N, Rawshani A, Franzen S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228–2237. .
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772. .
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
   PubMed Web of Science ®Google Scholar
• Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973–1974.
   PubMed Web of Science ®Google Scholar
• Taskinen M-R, BorénJ. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–495.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319–335.
   PubMed Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes. 2016;65(7):1767–1778.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36(1):131–147.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–229.
   PubMed Web of Science ®Google Scholar
• Dash S, Xiao C, Morgantini C, et al. New insights into the regulation of chylomicron production. Annu Rev Nutr. 2015;35(1):265–294.
   PubMed Web of Science ®Google Scholar
• Nogueira JP, Maraninchi M, Beliard S, et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2012;32(4):1039–1044. .
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733–749.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–666. .
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–233. .
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. .
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C–lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364–373. .
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298–1309.
   PubMed Web of Science ®Google Scholar
• Balling M, Afzal S, Varbo A, et al. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. J Am Coll Cardiol. 2020;76(23):2725–2735.
   PubMed Web of Science ®Google Scholar
• Castañer O, Pintó X, Subirana I, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76(23):2712–2724. .
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S125–S150. .
   PubMed Web of Science ®Google Scholar
• Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731–754. .
   PubMed Web of Science ®Google Scholar
• Yoshino M, Kayser BD, Yoshino J, et al. Effects of diet versus gastric bypass on metabolic function in diabetes. N Engl J Med. 2020;383(8):721–732. .
   PubMed Web of Science ®Google Scholar
• Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–1576. .
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S111–S124. .
   PubMed Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism. Diabetes. 2015;64(7):2310–2318.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;12(11):1267–1271.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. .
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. .
   PubMed Web of Science ®Google Scholar
• Cha S-A, Park Y-M, J-s Y, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16(1):58. .
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–286. .
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. .
   PubMed Web of Science ®Google Scholar
• Ray KK, Leiter LA, Muller-Wieland D, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018;20(6):1479–1489. .
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al., Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Eng J Med. 380(1): 11–22. 2019. .
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society consensus panel. Eur Heart J. 2017;38(32):2459–2472. .
   PubMed Web of Science ®Google Scholar
• Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117(9):1444–1448.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546–1553.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26:107–139.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;2019(73):3168–3209.
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;2020(41):111–188.
   Google Scholar
• Mancini GBJ, Hegele RA, Leiter LA. Dyslipidemia. Can J Diabetes. 2018;42(Suppl 1):S178–S185.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564. .
   PubMed Web of Science ®Google Scholar
• Peto R, Collins R. Trust the blinded randomized evidence that statin therapy rarely causes symptomatic side effects. Circulation. 2018;138(15):1499–1501.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012–1022.
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23(8):1209–1230.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). Circulation. 2018;137(15):1571–1582.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2(5):547–555.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Alirocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17(5):633–643.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Evolocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17(5):1447–1461.
   PubMed Web of Science ®Google Scholar
• Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014;35(33):2249–2259. .
   PubMed Web of Science ®Google Scholar
• Toth PP, Jones SR, Monsalvo ML, et al. Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies. J Am Heart Assoc. 2020;9(5):e014129.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Eng J Med. 2018;379(22):2097–2107. .
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–950.
   PubMed Web of Science ®Google Scholar
• Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the Fourier randomized clinical trial. JAMA Cardiol. 2021;6(2):139–147.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962–1971.
   PubMed Web of Science ®Google Scholar
• Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:618–628.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Jayanna MB, Brown AS, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019;13(4):525–537.
   PubMed Web of Science ®Google Scholar
• Nishikido T, Ray KK. Inclisiran for the treatment of dyslipidemia. Expert Opin Investig Drugs. 2018;27(3):287–294.
   PubMed Web of Science ®Google Scholar
• Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–16961.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41-51.
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519.
   PubMed Web of Science ®Google Scholar
• A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). Accessed 3 Jan 2021. Available from: clinicaltrials.gov/ct2/show/NCT03705234.
   Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–2093.
   PubMed Web of Science ®Google Scholar
• Simental-Mendia LE, Simental-Mendia M, Sanchez-Garcia A, et al. Effect of fibrates on glycemic parameters: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2018;132:232–241.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–1245. .
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment [see comments]. Circulation. 1992;85(1):37–45. .
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341(6):410–418. .
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. Jama. 2001;285(12):1585–1591. .
   PubMed Web of Science ®Google Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001;357(9260):905–910. .
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697. .
   PubMed Web of Science ®Google Scholar
• Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373(9677):1780–1788. .
   PubMed Web of Science ®Google Scholar
• Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370–380. .
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–1884. .
   PubMed Web of Science ®Google Scholar
• Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.
   PubMed Web of Science ®Google Scholar
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT). Accessed 3 Jan 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03071692.
   Google Scholar
• Fruchart J-C, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the residual risk reduction initiative (R3i) foundation. Cardiovasc Diabetol. 2019;18(1):71. .
   PubMed Web of Science ®Google Scholar
• Ooi EM, Watts GF, Ng TW, et al. Effect of dietary fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients. 2015;7(6):4416–4425.
   PubMed Web of Science ®Google Scholar
• GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico).Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Lancet. 1999;354(9177):447–455.
   PubMed Web of Science ®Google Scholar
• Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018;3(3):225–234.
   PubMed Web of Science ®Google Scholar
• Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.
   PubMed Web of Science ®Google Scholar
• The ASCENDStudy Collaborative Group, Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540–1550.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73(7):1283–1290.
   PubMed Web of Science ®Google Scholar
• Sasaki J, Yokoyama M, Matsuzaki M, et al. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA lipid intervention study (JELIS). J Atheroscler Thromb. 2012;19(2):194–204.
   PubMed Web of Science ®Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020;22(Supplement_J):J34–J48.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925–3932.
   Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al., Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 324(22): 2268–2280. 2020.
   PubMed Web of Science ®Google Scholar
• Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35(1400–1411):e1401–1403.
   Google Scholar
• Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94–106.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendia LE, Mikhailidis DP, et al. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2018;50(7):565–575.
   PubMed Web of Science ®Google Scholar
• FDA approves use of Vascepa (icosapent ethyl) to reduce risk of cardiovascular events in certain adult patient groups. 13 Dec 2019. Accessed1 Mar 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups.
   Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Jones MR, Nwose OM. Role of colesevelam in combination lipid-lowering therapy. Am J Cardiovasc Drugs. 2013;13(5):315–323.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Karimi E, et al. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2017;227:850–857.
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8):20B–26B.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314–345.
   PubMed Web of Science ®Google Scholar
• Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm. 2003;60(suppl_2):S9–14. quiz S25.
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Eng J Med. 2009;361(22):2113–2122. .
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512–3517.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019;124(3):386–404.
   PubMed Web of Science ®Google Scholar
• Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
   PubMed Web of Science ®Google Scholar
• Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017;26(2):251–259.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7(1):13457. .
   PubMed Web of Science ®Google Scholar
• Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR outcomes). Accessed 3 Jan 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02993406.
   Google Scholar
• Bempedoic acid FDA approval. Drugs@FDA: FDA-approved drugs. Feb/ 21/2020. Accessed1 Mar 2020. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211616.
   Google Scholar
• Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022–1032.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–221.
   PubMed Web of Science ®Google Scholar
• Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308–1317.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, et al., Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 383(8): 711–720. 2020.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Eng J Med. 2017;377(3):296–297.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470–486.
   PubMed Web of Science ®Google Scholar
• FDA approves add-on therapy for patients with genetic form of severely high cholesterol. 11/Feb/2021. Accessed17 Feb 2021. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol.
   Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222–232.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–2206.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531–542.
   PubMed Web of Science ®Google Scholar
• Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408–1415.
   PubMed Web of Science ®Google Scholar
• Paik J, Duggan S. Volanesorsen: first global approval. Drugs. 2019;79(12):1349–1354.
   PubMed Web of Science ®Google Scholar
• Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40(33):2785–2796. .
   PubMed Web of Science ®Google Scholar
• Tsimikas S. RNA-targeted therapeutics for lipid disorders. Curr Opin Lipidol. 2018;29(6):459–466.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982–2994.
   PubMed Web of Science ®Google Scholar
• Saeed A, Sun W, Agarwala A, et al. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the atherosclerosis risk in communities study. Atherosclerosis. 2019;282:52–56.
   PubMed Web of Science ®Google Scholar
• Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care. 2019;42:1312–1318.
   PubMed Web of Science ®Google Scholar
• Poli A, Barbagallo CM, Cicero AFG, et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res. 2018;134:51–60.
   PubMed Web of Science ®Google Scholar
• Baumgartner S, Bruckert E, Gallo A, et al. The position of functional foods and supplements with a serum LDL-C lowering effect in the spectrum ranging from universal to care-related CVD risk management. Atherosclerosis. 2020;311:116–123.
   PubMed Web of Science ®Google Scholar
• Pirro M, Vetrani C, Bianchi C, et al. Joint position statement on “nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017;27(1):2–17.
   PubMed Web of Science ®Google Scholar
• Gylling H, Strandberg TE, Kovanen PT, et al. Lipoprotein cholesterol concentration with plant stanol esters to reduce the risk of atherosclerotic cardiovascular disease events at a population level: a critical discussion. Nutrients. 2020;12(8):12.
   Web of Science ®Google Scholar
• Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
   PubMed Web of Science ®Google Scholar
• Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243(2):449–461.
   PubMed Web of Science ®Google Scholar
• Pothuraju R, Sharma RK, Onteru SK, et al. Hypoglycemic and hypolipidemic effects of aloe vera extract preparations: a review. Phytother Res. 2016;30(2):200–207.
   PubMed Web of Science ®Google Scholar
• Shakib Z, Shahraki N, Razavi BM, et al. Aloe vera as an herbal medicine in the treatment of metabolic syndrome: a review. Phytother Res. 2019;33(10):2649–2660.
   PubMed Web of Science ®Google Scholar
• Suksomboon N, Poolsup N, Punthanitisarn S. Effect of aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(2):180–188.
   PubMed Web of Science ®Google Scholar
• Rawshani A, Franzen S, Eliasson B, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–1418. .
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644.
   PubMed Web of Science ®Google Scholar
• Khunti K, Ceriello A, Cos X, et al. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137–148.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72(25):3320–3331.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. .
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505.
   PubMed Web of Science ®Google Scholar